270 related articles for article (PubMed ID: 33219572)
41. Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.
Abou Rahal J; Ishak RS; Otrock ZK; Kibbi AG; Taher AT
J Thromb Thrombolysis; 2012 Nov; 34(4):541-4. PubMed ID: 22592843
[TBL] [Abstract][Full Text] [Related]
42. In critically ill patients with COVID-19, therapeutic anticoagulation did not increase organ support-free days.
Donato AA
Ann Intern Med; 2021 Dec; 174(12):JC135. PubMed ID: 34871054
[TBL] [Abstract][Full Text] [Related]
43. Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports.
Guo D; Pan S; Wang M; Guo Y
Undersea Hyperb Med; 2020; 47(2):181-187. PubMed ID: 32574433
[TBL] [Abstract][Full Text] [Related]
44. COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations.
Levy JH; Iba T; Olson LB; Corey KM; Ghadimi K; Connors JM
Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):29-35. PubMed ID: 34288441
[TBL] [Abstract][Full Text] [Related]
45. The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.
Paganini M; Bosco G; Perozzo FAG; Kohlscheen E; Sonda R; Bassetto F; Garetto G; Camporesi EM; Thom SR
Adv Exp Med Biol; 2021; 1289():27-35. PubMed ID: 32696443
[TBL] [Abstract][Full Text] [Related]
46. Hyperbaric oxygen therapy in long-COVID-19 disease.
García Estévez DA; López Pérez Á; Gómez Márquez H
Med Clin (Barc); 2023 Dec; 161(11):498-499. PubMed ID: 37775412
[No Abstract] [Full Text] [Related]
47. [SARS-CoV-2 infection as a thrombo-inflammatory endothelial disease].
Samaniego F; Conte G
Rev Med Chil; 2020 Oct; 148(10):1467-1474. PubMed ID: 33844717
[TBL] [Abstract][Full Text] [Related]
48. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
[TBL] [Abstract][Full Text] [Related]
49. Hyperbaric oxygen therapy for paediatric patients: an unintended consequence of the COVID-19 pandemic.
El Hawa AAA; Bekeny JC; Phillips NW; Johnson-Arbor K
J Wound Care; 2021 Sep; 30(Sup9):S24-S28. PubMed ID: 34554855
[TBL] [Abstract][Full Text] [Related]
50. Cutaneous manifestations of SARS-CoV-2 infection: a clinical update.
Gisondi P; PIaserico S; Bordin C; Alaibac M; Girolomoni G; Naldi L
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2499-2504. PubMed ID: 32585074
[TBL] [Abstract][Full Text] [Related]
51. [Learning with COVID-19: what about anticoagulation?].
Álvarez-Rodríguez E; González González R; Torres-Gárate R; López-Riquelme P; González Martil I; Abad Cuñado V
An Sist Sanit Navar; 2020 Aug; 43(2):251-254. PubMed ID: 32865189
[TBL] [Abstract][Full Text] [Related]
52. Hyperbaric oxygen therapy for the treatment of long COVID.
Wilmshurst P; Bewley S; Murray P
Clin Med (Lond); 2023 Jan; 23(1):99-100. PubMed ID: 36697009
[No Abstract] [Full Text] [Related]
53. COVID-19 and implications for dermatological and allergological diseases.
Buhl T; Beissert S; Gaffal E; Goebeler M; Hertl M; Mauch C; Reich K; Schmidt E; Schön MP; Sticherling M; Sunderkötter C; Traidl-Hoffmann C; Werfel T; Wilsman-Theis D; Worm M
J Dtsch Dermatol Ges; 2020 Aug; 18(8):815-824. PubMed ID: 32717116
[TBL] [Abstract][Full Text] [Related]
54. Hyperbaric oxygen therapy for COVID-19 patients with respiratory distress: treated cases versus propensity-matched controls.
Gorenstein SA; Castellano ML; Slone ES; Gillette B; Liu H; Alsamarraie C; Jacobson AM; Wall SP; Adhikari S; Swartz JL; McMullen JJS; Osorio M; Koziatek CA; Lee DC
Undersea Hyperb Med; 2020; 47(3):405-413. PubMed ID: 32931666
[TBL] [Abstract][Full Text] [Related]
55. Diving and hyperbaric medicine in the SARS-CoV-2 pandemic.
Mitchell SJ
Diving Hyperb Med; 2020 Jun; 50(2):90-91. PubMed ID: 32557408
[No Abstract] [Full Text] [Related]
56. Deep vein thrombosis in noncritically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in nonintensive care unit patients.
Jimenez-Guiu X; Huici-Sánchez M; Rmera-Villegas A; Izquierdo-Miranda A; Sancho-Cerro A; Vila-Coll R
J Vasc Surg Venous Lymphat Disord; 2021 May; 9(3):592-596. PubMed ID: 32911110
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic Anticoagulation with Heparin in Patients with Covid-19.
Sterpetti AV
N Engl J Med; 2021 Nov; 385(21):2013-2014. PubMed ID: 34788516
[No Abstract] [Full Text] [Related]
58. Therapeutic Anticoagulation with Heparin in Patients with Covid-19.
Fernandes TM; McGuire WC; Morris TA
N Engl J Med; 2021 Nov; 385(21):2013. PubMed ID: 34788515
[No Abstract] [Full Text] [Related]
59. Secondary livedoid vasculopathy following SARS-CoV-2 infection.
Carballido Vázquez AM; Vega López TL; Manchado López P; Martínez García G; Mateos Mayo A
J Eur Acad Dermatol Venereol; 2024 May; 38(5):e368-e370. PubMed ID: 38095220
[No Abstract] [Full Text] [Related]
60. Anticoagulation in COVID-19.
Bradbury CA; McQuilten Z
Lancet; 2022 Jan; 399(10319):5-7. PubMed ID: 34921757
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
